As the cell and gene therapy industry continues to develop at a rapid pace, the ability to manufacture clinical grade viral vectors at a commercial scale is now more crucial than ever before. But how do you decide which vector is most suited to your particular needs, and how should you best approach process development and manufacture to achieve optimal outcomes?
In this free webinar, Behnam Ahmadian Baghbaderani (Global Head of Process Development, Lonza), Xin Swanson (Head of Viral Vector Commercial Development, Lonza) and Suparna Sanyal (Innovation & Commercial Integration Manager, Lonza), will discuss:
The Lonza logo is a Lonza Ltd. Trademark